• 1
    Friedmann SL. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. N Engl J Med 1993; 328:18281835.MEDLINE
  • 2
    Lewin MJM. The somatostatin receptor in the GI tract. Annu Rev Physiol 1992; 54:455468.MEDLINE
  • 3
    Cerini R, Lee S, Hadengue A, Koshy A, Girod C, Lebrec D. Circulatory effects of somatostatin analogue in two conscious rats models of portal hypertension. Gastroenterology 1988; 94:703708.MEDLINE
  • 4
    Pizcueta P, Garcia-Pagan J, Fernandez M, Casamitjana R, Bosch J, Rodès J. Glucagon hinders the effects of somatostatin on portal hypertension. A study in rats with partial portal vein ligation. Gastroenterology 1991; 101:17101715.MEDLINE
  • 5
    Hori N, Okanoue T, Sawa Y, Itoh Y, Mori T, Takami S. Hemodynamic effects of combined treatment with somatostatin analogue (SMS 201–995) and low-dose isosorbide dinitrate on portal hypertension in conscious cirrhotic rats. J Gastroenterol 1994; 29:460468.MEDLINE
  • 6
    Jenkins SA, Baxter JN, Corbett WA, Shields R. The effects of somatostatin analogue SMS 201–995 on hepatic haemodynamics in the cirrhotic rat. Br J Surg 1985; 72:864867.MEDLINE
  • 7
    Tracy T, Tector J, Goerke M, Kitchen S, Lagunoff D. Somatostatin analogue (octreotide) inhibits bile duct epithelial proliferation and fibrosis after extrahepatic biliary obstruction. Am J Pathol 1993; 143:15741578.MEDLINE
  • 8
    Rubio CA, Porwitt A. Quantitation of fibrosis in liver biopsies. Anal Quant Cytol Histol 1988; 10:107109.MEDLINE
  • 9
    Oberti F, Pilette C, Rifflet H, Maiga M, Moreau A, Gallois Y, Girault A, et al. Effects of simvastatin, pentoxyfylline and spironolactone on hepatic fibrosis and portal hypertension in cirrhotic rats. J Hepatol 1997; 26:13631371.MEDLINE
  • 10
    Halvorsen JF, Myking AO. The porto-systemic collateral pattern in the rat. Eur Surg Res 1974; 6:183195.MEDLINE
  • 11
    Lebrec D. Animals models of portal hypertension. In: OkudaK, BenhamouJP, eds. Portal Hypertension: Clinical and Physiological Aspects. Tokyo: Springer-Verlag. 1991;10113.
  • 12
    Proctor E, Chatamra K. High yield micronodular cirrhosis in the rat. Gastroenterology 1982; 83:11831190.MEDLINE
  • 13
    Geraghty JG, Angerson WJ, Carter DC. Portal venous pressure and portosystemic shunting in experimental portal hypertension. Am J Physiol 1989; 257:G52G57.MEDLINE
  • 14
    Chojkier M, Groszmann RJ. Measurement of portal-systemic shunting in the the rat using γ-labeled microspheres. Am J Physiol 1981; 240:G371G375.MEDLINE
  • 15
    Jamall IS, Finelli VN, Que Hee SS. A simple method to determine nanogram levels of 4-hydroxyproline in biological tissues. Anal Biochem 1981; 112:7075.MEDLINE
  • 16
    Chomczinski P, Sacchi N. Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162:156159.MEDLINE
  • 17
    Puissant C, Houdebine I-M. An improvement of the single-step method of RNA isolation by acid guanidium-phenol-chloroform extraction. Biotechniques 1990; 8:148149.MEDLINE
  • 18
    Scharzbauer JE, Tamkun JW, Lemischka IR, Hynes RO. Three different fibronectin mRNAs arise by alternative splicing within the coding region. Cell 1983; 35:421431.MEDLINE
  • 19
    Selden C, Farnaud S, Ding SF, Habib N, Foster C, Hodgson H. Expression of hepatocyte growth factor mRNA, and c-met mRNA (hepatocyte growth factor receptor) in human liver tumours. J Hepatol 1994; 21:227234.MEDLINE
  • 20
    Karalis K, Mastorakos G, Chrousos GP, Tolis G. Somatostatin analogues suppress the inflammatory reaction in vivo. J Clin Invest 1994; 93:20002006.MEDLINE
  • 21
    Orda R, Ellis H. Self-established porto-caval and porto-pulmonary shunts in mechanically induced portal hypertension. Eur Surg Res 1978; 10:172183.MEDLINE
  • 22
    Bono RF, Moreno AH, Rousselot LM, Panke WF. Studies on portal hypertension. V. A comparison between the experimentallly induced state of portal hypertension and that observed in human beings. Surgery 1960; 48:119141.
  • 23
    Tanoue K, Kitano S, Hashizume M, Wada H, Sugimachi K. A rat model of esophageal varices. Hepatology 1991; 13:3538.MEDLINE
  • 24
    Chojkier M, Groszmann RJ. Measurement of portal-systemic shunting in the rat using γ-labeled microspheres. Am J Physiol 1981; 240:G371G375.MEDLINE
  • 25
    Gerathy JG, Angerson WJ, Carter DC. Portal venous pressure and portosystemic shunting in experimental portal hypertension. Am J Physiol 1989; 257:G52G57.MEDLINE
  • 26
    Lin HC, Yang C-M, Hou M-C, Li S-M, Huang Y-T, Yu P-C, Tsai YT, et al. Effects of long term administration of octreotide in portal vein stenosed rats. Hepatology 1996; 23:537543.MEDLINE
  • 27
    Stauber RE, Ruthardt FW, Tauxe WN, Van Thiel DH. Evaluation of portal-systemic shunting in rats from mesenteric and splenic beds. Dig Dis Sci 1991; 36:209215.MEDLINE
  • 28
    D'Almeida MS, Gaudin C, Lebrec D. Validation of 1- and 2-mm transit time ultrasound flow probes on mesenteric artery and aorta of rats. Am J Physiol 1995; 268:H1368H1372.MEDLINE
  • 29
    D'Almeida M, Caimail S, Lebrec D. Validation of portal blood flow measurement by transit-time ultrasound flow probes on the portal vein of conscious rats. Am J Physiol 1996; 271:H2701H2709.MEDLINE
  • 30
    Oberti F, Veal N, Fort J, Pilette C, Calès P. Portosystemic blood flow and cardiac output measured by transit ultrasound in cirrhotic rats [Abstract]. Hepatology 1997; 26:393A.
  • 31
    Cales P, Oberti F, Veal N, Fort J, Kaassis M, Moal F, Aube C, et al. Measurement of an index of collateral blood flow in rats with portal hypertension. Hepatology 1998 (in press).
  • 32
    Oberti F, Rifflet H, Maïga M, Pilette C, Gallois Y, Dovay O, La Jeune JJ, et al. Prevention of portal hypertension by propranolol and spironolactone, alone or in combination, in rats with bile duct ligation. J Hepatol 1997; 26:167173.MEDLINE
  • 33
    Lin HC, Soubrane O, Cailmail S, Lebrec D. Early chronic administration of propranolol reduces the severity of portal hypertension and portal-systemic shunts in conscious portal vein stenosed rats. J Hepatol 1991; 13:213219.MEDLINE
  • 34
    Lee F-Y, Colombato L, Albillos A, Groszmann R. Administration of Nω-nitro-l-arginine ameliorates portal systemic shunting in portal-hypertensive rats. Gastroenterology 1993; 105:14641670.MEDLINE
  • 35
    Colombato LA, Albillos A, Genecin P, Sarin S, Groszmann RJ. Prevention of portal systemic shunting in propranolol-treated and in sodium-restricted cirrhotic rats. Gastroenterology 1990; 100:A730.
  • 36
    Lin HC, Tsai YT, Yang MCM, Lee FY, Hou MC, Chen LS, Lee S. Effect of octreotide on total effective vascular compliance in patients with posthepatitic cirrhosis. J Hepatol 1996; 24:8187.MEDLINE
  • 37
    Møller S, Brinch K, Henriksen JH, Becker U. Effect of octreotide on splanchnic, systemic, and central haemodynamics in cirrhosis. J Hepatol 1996; 25(Suppl 1):175.
  • 38
    Albillos A, Colombato L, Lee FY, Groszmann R. Octreotide ameliorates vasodilatation and Na+ retention in portal hypertensive rats. Gastroenterology 1993; 104:575579.MEDLINE
  • 39
    Sieber C, Mosca G, Groszmann J. Effects of somatostatin on mesenteric vascular resistance in normal and portal hypertensive rats. Am J Physiol 1992; 262:G274G277.MEDLINE
  • 40
    Sieber C, Lee F-Y, Groszmann RJ. Long term octreotide treatment prevents vascular hyporeactivity in portal hypertensive rats. Hepatology 1996; 23:12181223.MEDLINE
  • 41
    Oberti F, Veal N, Kaassis M, Rifflet H, Pilette C, Cales P. Hemodynamic effects of terlipressin and octreotide administration alone or in combination in portal hypertensive rats. Gastroenterology 1996; 110:A1281.
  • 42
    Groupe Français de la Prévention Pré-Primaire. Propranolol does not decrease the development of large esophageal varices in patients with cirrhosis. A controlled study. Hepatology 1995; 22(4 Pt 2):155A.